Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 2, 2008, Pages 133-139

  Han, Ke Qi ^a   Huang, Guang ^a   Gao, Chun Fang ^b   Wang, Xiu Li ^b   Ma, Bo ^b   Sun, Liang Qi ^b   Wei, Zhi Jie ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b The 150th Central Hospital of People's Liberation Army   (China)

Author keywords

Biomarker; Classification and regression tree (CART); Lung cancer; Mass spectrometry; Serum biomarkers; Surface enhanced laser desorption ionization (SELDI)

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; ALGORITHMS; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 42049104807     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318145b98b     Document Type: Article

References (28)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics 2004. CA Cancer J Clin. 2004;54:8-29.
2. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867-1876.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392.
4. Wu CC, Chien KY, Tsang NM, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics. 2005;5:3173-3182.
5. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers over expressed in cancer tissue and serum. Proc Natl Acad Sci USA. 2003;100:3410-3415.
6. Seemann MD, Beinert T, Furst H, et al. An evaluation of the tumor markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer. 1999;26:149-155.
7. Schneider J, Velcovsky HG, Morr H, et al. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res. 2000;20:5053-5058.
8. Schneider J, Bitterlich N, Velcovsky HG, et al. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol. 2002;7:145-151.
9. Hanash SM. Global profiling of gene expression in cancer using genomics and proteomics. Curr Opin Mol Ther. 2001;3:538-545.
10. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteo-mics. Translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1:683-695.
11. Hutchen TW, Yip TT. New desorption strategies for the mass spectrumetric analysis of macromolecules. Rapid Commun Mass Spectrom. 1993;7:576-580.
12. Wadsworth JT, Somers KD, Cazares LH, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res. 2004;10:1625-1632.
13. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868-1875.
14. Cazares LH, Adam BL, Ward MD, et al. Normal benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res. 2002;8:2541-2552.
15. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res. 2004;10:860-868.
16. Matthias P, Ebert A, Meuer J, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res. 2004;3:1261-1266.
17. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48:1296-1304.
18. Ho DWY, Yang ZF, Wong BYH, et al. Surface-enhanced laser desorption/ionization time of- flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer. 2006;107:99-106.
19. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology. 2005;41:40-47.
20. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
21. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609-3614.
22. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001;158:1491-1502.
23. Xiao X, Wei XP, He DC. Proteomic approaches to biomarker discovery in lung cancers by SELDI technology. Science in China series C. Life Sci. 2003;46:531-537.
24. Yang SY, Xiao XY, Zhang WG, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005;5:83.
25. Hicks RJ, Lau E, Alam NZ, et al. Imaging in the diagnosis and treatment of non-small cell lung cancer. Respirology. 2007;12:165-172.
26. Bellomi M, Rampinelli C, Funicelli L, et al. Screening for lung cancer. Cancer Imaging. 2006;31:S9-S12.
27. Espina V, Dettloff KA, Cowherd S, et al. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther. 2004;4:83-93.
28. Adam BL, Viahou A, Semmes OJ, et al. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics. 2001;1:1264-1270.